{"id":"W4379333780","doi":"10.1200/jco.2023.41.16_suppl.tps7590","title":"MAHOGANY: A phase 3 trial of zanubrutinib plus anti-CD20 antibodies vs lenalidomide plus rituximab in patients with relapsed or refractory follicular or marginal zone lymphoma.","year":2023,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"BeiGene","keywords":"Medicine; Obinutuzumab; Lenalidomide; Rituximab; Internal medicine; Ibrutinib; Oncology; Idelalisib; Follicular lymphoma; Chronic lymphocytic leukemia; Bruton's tyrosine kinase; Gastroenterology; Lymphoma; Leukemia; Multiple myeloma; Tyrosine kinase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009362659,0.001133362,0.001378113,0.0004240739,0.0004520187,0.001190659,0.001236294,0.001274086,0.009324683],"category_scores_gemma":[0.0008826968,0.0004170082,0.001272398,0.000347222,0.0008324768,0.0009710102,0.0005351296,0.003035338,0.0014451],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001302719,"about_ca_system_score_gemma":0.001359476,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001732017,"about_ca_topic_score_gemma":0.008815291,"domain_scores_codex":[0.9996518,0.0001704693,0.000009796936,0.00004951419,0.00003313736,0.00008530192],"domain_scores_gemma":[0.9996402,0.00007144336,0.00007129282,0.00002191497,0.00002006081,0.0001751093],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8708954,0.01124077,0.002467993,0.00174479,0.001648153,0.0001945105,0.0003433433,0.001817787,0.01458186,0.001143843,0.01481194,0.07910967],"study_design_scores_gemma":[0.9148262,0.06750953,0.006552773,0.0001487602,0.0006438966,0.0002389833,0.00009489027,0.001498374,0.000917657,0.0007267241,0.00679234,0.00004989596],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9656652,0.008511694,0.0007346928,0.002471624,0.0006382349,0.003750846,0.004748596,0.0004629965,0.01301614],"genre_scores_gemma":[0.9766071,0.003133845,0.001646683,0.002698031,0.0002729775,0.003510682,0.0042737,0.00008306286,0.007773903],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009324683,"threshold_uncertainty_score":0.03119415,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1181807333488685,"score_gpt":0.4680301710243539,"score_spread":0.3498494376754854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}